Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray, Inc. (TLRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Earnings Preview: Tilray, Inc. (TLRY) Q2 Earnings Expected to Decline

Canopy Growth

CannTrust Holdings

HEXO Corp

MedMen Enterprises Inc.

Aurora Cannabis

Aphria

Cronos Group

OrganiGram Holdings Inc.

The outlook for cannabis stocks isn't nearly as green as it used to be.

Earnings Estimates Are Plunging for These 12 Pot Stocks

GW Pharmaceuticals

Cannabis stocks bounced back on Friday, trading higher in sympathy with a big earnings beat and 35% gain from Aphria Inc (NYSE: APHA).

Cannabis Stocks Are The Latest Target Of Short Sellers

Village Farms International

Pessimism may be waning for these three popular cannabis stocks.

The Only 3 Pot Stocks With Declining Short Interest

TLRY stock could only be suitable for investors with high risk appetite and might hedge Tilray positions with covered calls or put spreads.
The post Cannabis Stock Watchers Wonder: Can Tilray Stock Top $50 Anytime Soon?

Cannabis Stock Watchers Wonder: Can Tilray Stock Top $50 Anytime Soon?

In the next few quarters, marijuana stocks will trade higher if the underlying company reports higher revenue and shrinking operating costs. The closer the company reaches profitability, the more likely the stock will rebound.

5 Marijuana Stocks to Buy Before They Rebound

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Innovative Industrial Properties

Trulieve Cannabis Corp.

These are the only cannabis stocks with a billion-dollar valuation.

The 13 Largest Marijuana Stocks in the World

Despite falling from the highs, TLRY has potential. Here are three potential positive catalysts that could unlock Tilray's potential.

3 Potential Catalysts That Could Send Tilray Shares Soaring

The July 15 short interest data have been compared with the previous figures, and short interest in most of these selected marijuana stocks increased.

Short Sellers - Get Even Higher on Cannabis Stocks

Tilray stock has rallied slightly since the beginning of June. Now trading around $42, TLRY still isn’t a buy.

Around $35, Tilray Stock Is a Buy

Canadian pot company Tilray has acquired U.K.-based Smith & Sinclair to create a brand of CBD-infused edibles to sell in the U.S.

Tilray acquires boozy candy company Smith & Sinclair to develop CBD edibles

Rapid sales growth yields no guarantee of profitability in the cannabis space.

Will Aurora, Canopy, Cronos, and Tilray Be Profitable by 2021?

Tilray's longer-term outlook remains murky.

Where Will Tilray Be in 5 Years?

TLRY stock has been, still is, and will remain the most volatile pot stock in the market.
The post Here’s Why Tilray Stock Is A High-Risk, High-Reward Situation appeared first on InvestorPlace.

Here’s Why Tilray Stock Is A High-Risk, High-Reward Situation

No green flag for cannabis in the U.S., at least at the federal level, anytime soon.

7 Reasons Marijuana Has Virtually No Chance of Being Legalized in the U.S. Before 2021

A new report projects nearly $24 billion in U.S. cannabidiol sales by 2023.

U.S. CBD Sales to Grow an Average of 107% Annually Through 2023

Canadian cannabis companies have leapt onto U.S. stock markets, dazzling investors.

Mapping Out Canada's Cannabis Invasion Of The U.S.

On Thursday, Tilray Inc (NASDAQ: TLRY) announced its GMP-certified medical cannabis oral solution has reached Ireland.

Tilray's Medical Cannabis Oil Reaches Ireland

Tilray may not have done well in terms of the print, but TLRY stock could still jump higher on the company's transformative partnerships.
The post ‘High’ Caliber: Can Tilray Stock Close the Credibility Gap?

‘High’ Caliber: Can Tilray Stock Close the Credibility Gap?

Cannabis stocks had a huge showing on Wall Street last fall. In fact, most of the news flow surrounding these stocks had investors pouring money into them.

Short Sellers Get Even Higher on Cannabis Stocks.

Pessimism is peaking for these three popular marijuana growers.

3 Pot Stocks Short-Sellers Are Targeting

A share lock-up has boosted TLRY in recent weeks, but Tilray stock will likely continue to fall as fundamentals begin to take hold.
The post The Fundamental Problems of Tilray Stock Are Just Getting Worse appeared first on InvestorPlace.

The Fundamental Problems of Tilray Stock Are Just Getting Worse

Rapid sales growth won't save these popular pot stocks from another year of red ink.

Marijuana's "Big Four" Stocks Will Likely Lose Money in 2020

Scotts Miracle-Gro

Add another marijuana stock to the exchange's lineup, and join the growing crowd ordering burritos at the popular Mexican fast-casual restaurant chain.

Marijuana Stock ETF to Start Trading, Chipotle Cruises to a New High

A number of popular pot stocks regained their luster last month.

News for Tilray Brands Stock (TLRY)